Growth hormone in pediatric chronic kidney disease: more than just height

Area of Science:

• Pediatric Nephrology
• Endocrinology
• Growth Hormone Therapy

Background:

• Recombinant human growth hormone (rhGH) therapy is standard for pediatric chronic kidney disease (CKD) patients with growth impairment.
• Growth hormone (GH) use varies, with some centers showing low uptake.
• Focus has been on height, overlooking other crucial multisystem effects in CKD.

Purpose of the Study:

• To review current knowledge on the multisystem effects of GH therapy in pediatric CKD.
• To identify areas needing further clinical research.
• To inform treatment decisions by providing comprehensive data.

Main Methods:

• Literature review of existing studies on GH therapy in pediatric CKD.
• Inclusion of clinical data from children and adults treated with GH for non-CKD indications.
• Synthesis of current knowledge on GH's impact on pediatric growth and development in CKD.

Main Results:

• GH therapy impacts multiple organ systems beyond linear growth in pediatric CKD.
• Data on non-height-related effects of GH in CKD are less comprehensive.
• GH has been used for various indications, providing some comparative data.

Conclusions:

• A comprehensive understanding of GH's multisystem effects is crucial for pediatric CKD patients.
• More robust clinical studies are needed to fully elucidate these effects.
• Informed decision-making for families regarding GH therapy requires broader evidence.